Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GIL YOSIPOVITCH

Allopathic & Osteopathic Physicians Dermatology

NPI
1679558027
CMS profile
30973
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$231,845.37

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GIL YOSIPOVITCH

NPI 1679558027 · CMS profile ID 30973

Allopathic & Osteopathic Physicians / Dermatology

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679558027?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GIL YOSIPOVITCH, NPI 1679558027, CMS profile ID 30973. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679558027?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). GIL YOSIPOVITCH, NPI 1679558027, CMS profile ID 30973. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679558027?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
GIL YOSIPOVITCH, NPI 1679558027, CMS profile ID 30973, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679558027?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $231,845.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $65.9306/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431094 CMS
Novartis Pharmaceuticals Corporation $6,800.0006/15/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431096 CMS
Novartis Pharmaceuticals Corporation $462.9506/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431080 CMS
Mirum Pharmaceuticals, Inc. $111.1806/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123322497 CMS
Regeneron Pharmaceuticals, Inc. $681.7506/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114406774 CMS
ABBVIE INC. $750.0005/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106379372 CMS
Galderma Laboratories, L.P. $1,450.0005/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145336651 CMS
Amgen Inc. $125.1205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117420748 CMS
Amgen Inc. $125.1205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117420750 CMS
Amgen Inc. $125.0605/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117420752 CMS
SANOFI-AVENTIS U.S. LLC $1,910.0005/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139720514 CMS
Galderma Laboratories, L.P. $725.0005/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145336649 CMS
Mirum Pharmaceuticals, Inc. $144.6405/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123322495 CMS
Novartis Pharmaceuticals Corporation $23.1904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431098 CMS
Novartis Pharmaceuticals Corporation $220.3704/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431100 CMS
Novartis Pharmaceuticals Corporation $25.8804/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431102 CMS
Novartis Pharmaceuticals Corporation $297.3704/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431104 CMS
Novartis Pharmaceuticals Corporation $339.5404/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431106 CMS
Novartis Pharmaceuticals Corporation $7,400.0004/30/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431108 CMS
Novartis Pharmaceuticals Corporation $93.8804/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431110 CMS
Regeneron Healthcare Solutions, Inc. $1,910.0004/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114259706 CMS
Novartis Pharmaceuticals Corporation $497.7404/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431076 CMS
Novartis Pharmaceuticals Corporation $132.6504/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431082 CMS
Janssen Biotech, Inc. $27.3204/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078447097 CMS
GENZYME CORPORATION $909.0004/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139720592 CMS
Regeneron Pharmaceuticals, Inc. $89.3204/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114406772 CMS
Galderma Laboratories, L.P. $2,900.0003/29/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145336647 CMS
Galderma Laboratories, L.P. $145.4903/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145336645 CMS
Galderma Laboratories, L.P. $4,350.0003/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145336643 CMS
Regeneron Healthcare Solutions, Inc. $732.0003/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114259704 CMS
PFIZER INC. $106.7403/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131610829 CMS
Regeneron Pharmaceuticals, Inc. $78.8403/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114406770 CMS
GENZYME CORPORATION $500.0003/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139720502 CMS
GENZYME CORPORATION $500.0003/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139720504 CMS
GENZYME CORPORATION $500.0003/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139720506 CMS
GENZYME CORPORATION $250.0003/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139720580 CMS
GENZYME CORPORATION $250.0003/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139720582 CMS
Galderma Laboratories, L.P. $1,450.0003/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145336641 CMS
Regeneron Pharmaceuticals, Inc. $131.2103/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114406768 CMS
Janssen Biotech, Inc. $16.5002/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078449354 CMS
Novartis Pharmaceuticals Corporation $37.4502/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431078 CMS
Regeneron Healthcare Solutions, Inc. $19.3502/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114259702 CMS
Novartis Pharmaceuticals Corporation $104.0602/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087431074 CMS
Galderma Laboratories, L.P. $127.2402/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145336637 CMS
Galderma Laboratories, L.P. $24.5902/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145336639 CMS
Almirall LLC $800.0002/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120635153 CMS
GENZYME CORPORATION $1,818.0001/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139720746 CMS
GlaxoSmithKline, LLC. $6,000.0001/15/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116316572 CMS
PFIZER INC. $17.0801/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131203001 CMS
Regeneron Healthcare Solutions, Inc. $40.2001/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114259700 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71,821.79 85
PY2020 $82,549.00 27
PY2021 $100,422.66 41
PY2022 $178,694.57 82
PY2023 $205,887.08 122
PY2024 $231,845.37 151
PY2025 $178,484.60 125

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $45,605.49 12
PY2025 Principal investigator $498,325.11 28
PY2024 Recipient $19,721.38 13
PY2024 Principal investigator $158,525.44 43
PY2023 Recipient $27,164.34 50
PY2023 Principal investigator $667,845.30 77
PY2022 Recipient $22,723.81 28
PY2022 Principal investigator $769,822.80 20
PY2021 Recipient $38,832.57 50
PY2021 Principal investigator $260,905.37 26
PY2020 Recipient $27,491.53 26
PY2020 Principal investigator $159,909.87 19
PY2019 Recipient $105,340.26 9
PY2019 Principal investigator $131,541.40 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $17,639.00 12/22/2025 Non-covered Recipient Entity
Office Of Research Administration
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226107331
Recipient GENZYME CORPORATION $1,250.00 12/02/2025 Covered Recipient Physician Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1226120231
Recipient Novartis Pharmaceuticals Corporation $25,335.54 11/05/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291288
Recipient Regeneron Pharmaceuticals, Inc. $1,135.00 11/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184124050
Principal investigator 1 GENZYME CORPORATION $79,964.17 10/20/2025 Non-covered Recipient Entity
University Of Miami Umiami Medicine Dermatology
Severity of Atopic Dermatitis in skin of color: the Role of Type 2 Inflammation via Melanocytes, Fibromodulin, and Dendritic cells No dispute reported 06/30/2026 1226096306
Recipient GENZYME CORPORATION $500.00 10/10/2025 Covered Recipient Physician Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1226120235
Recipient GENZYME CORPORATION $250.00 10/10/2025 Covered Recipient Physician Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1226120238
Recipient GENZYME CORPORATION $500.00 09/17/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable No dispute reported 06/30/2026 1226120224
Recipient GENZYME CORPORATION $500.00 09/17/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable No dispute reported 06/30/2026 1226120227
Principal investigator 1 GENZYME CORPORATION $79,964.17 09/08/2025 Non-covered Recipient Entity
University Of Miami Umiami Medicine Dermatology
Severity of Atopic Dermatitis in skin of color: the Role of Type 2 Inflammation via Melanocytes, Fibromodulin, and Dendritic cells No dispute reported 06/30/2026 1226096311
Principal investigator 1 GENZYME CORPORATION $249,867.95 08/11/2025 Non-covered Recipient Entity
University Of Miami Office Of Research Administration Ora
ORIGINS: Cross Talk Between Melanocytes and Dendritic Cells Via OX40 Inducing an Increase in Inflammatory Skin Diseases of Skin of Color No dispute reported 06/30/2026 1226096438
Principal investigator 1 Novartis Pharmaceuticals Corporation $523.78 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI HEALTH SYSTEM
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313427
Principal investigator 1 SANOFI US SERVICES INC. $23,185.00 07/14/2025 Non-covered Recipient Entity
Office Of Research Administration
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226107225
Recipient PFIZER INC. $3,200.00 07/11/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228802974
Recipient Novartis Pharmaceuticals Corporation $2,178.61 07/07/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190292186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $680.00 06/23/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $950.00 06/23/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210284
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,900.00 06/23/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210326
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 06/23/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210330
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 06/23/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 06/23/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210342
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,050.00 06/23/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210358
Principal investigator 1 Incyte Corporation $5,440.00 06/05/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240480186
Principal investigator 1 Incyte Corporation $5,450.00 06/05/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240480190
Principal investigator 1 Incyte Corporation $9,295.00 06/05/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240480193
Principal investigator 1 Incyte Corporation $3,000.00 06/05/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240480198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $335.40 05/22/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184197859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $903.00 05/22/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184197861
Principal investigator 1 Incyte Corporation $58.00 05/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240608303
Principal investigator 1 Incyte Corporation $58.00 05/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240608306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $335.40 04/28/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184190721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $645.00 04/28/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184190723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,935.00 04/28/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184190725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,024.00 04/28/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184190733
Principal investigator 1 Incyte Corporation $159.00 04/01/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240608301
Recipient Regeneron Pharmaceuticals, Inc. $2,600.70 04/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184124048
Principal investigator 1 Amgen Inc. $965.24 03/25/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI HOSPITAL
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies No dispute reported 06/30/2026 1246650452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,398.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184173896
Recipient Regeneron Pharmaceuticals, Inc. $1,061.46 02/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184124046
Recipient Novartis Pharmaceuticals Corporation $7,094.18 01/13/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190292191